Reversal of Signs and Symptoms of a B-Cell Lymphoma in a Patient Using Only Low-Dose Naltrexone

Undefined
10
Average: 10 (1 vote)

Cited from the article:

Discussion
This case report describes the treatment of a 61-yearold
man with biopsy-proven FL. His initial physical
examination and PET/CT scan showed multiple
large, metabolically active, pathologic lymph nodes
that impressively demonstrated complete resolution
within 6 months of commencing therapy with nocturnally
administered LDN. This case not only suggests
the potential role of LDN in the treatment of
FLs but also highlights the ease of maintaining compliance
with this therapeutic regimen. In addition,
T.M. was prescribed a healthy diet, a nutritional supplement
regimen, and intravenous ALA. He did not
remain compliant with any of these 3 modalities.
Thus, in this case study, we are choosing to attribute
T.M.’s impressive achievement of clinical and radiological
remission to the LDN alone.
At the time of this report, and per telephone
communication from the patient’s wife, T.M.
remains asymptomatic from his disease, now 1 year
after his last CT/PET imaging. T.M. remained on
LDN for 6 months only; he stopped taking it in
June 2006. Perhaps these results represent a period
of spontaneous remission in the potential waxing
and waning course of his follicular lymphoma.
However, given the rapidity of the nodal waxing, its
equally rapid dimensional wane and the summarily
low cost of the medication, its ease of administration,
and possibility for efficacy, LDN deserves further
investigation.
We believe that by the mechanisms presented
herein, LDN demonstrates significant potential to
increase disease-free as well as overall survival in people
with FL. It is hoped that biomedical science will soon
develop cures for the currently incurable cancers,
perhaps via gene therapy, cancer vaccines, or other
biological platforms. Until that time, we need to consider
treatments that have the potential to alter the course of
cancers for the better. Especially needed are treatments
such as LDN that are inexpensive, demonstrate ease of
compliance, and are bereft of the side effects plaguing
most currently used conventional therapies.